Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action - RGRD Law

Core Viewpoint - Soleno Therapeutics Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to the safety and commercial viability of its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [1][4]. Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its only commercial product being diazoxide choline extended-release tablets (DCCR) [3]. Allegations of the Class Action Lawsuit - The lawsuit claims that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [4]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [4]. - A critical report by Scorpion Capital LLC raised concerns about DCCR, leading to a nearly 12% decline in Soleno's stock price over two trading days [5]. - Following the report, a patient death linked to DCCR was disclosed, resulting in a further approximately 19% decline in stock price [6]. - The financial results for Q3 2025 indicated a disruption in DCCR's launch trajectory, with a reported 27% decline in stock price after the announcement [7]. Legal Process - Investors who purchased Soleno common stock during the class period have until May 5, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1][8]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [9]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [10].